197 related articles for article (PubMed ID: 10217360)
1. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits.
Li J; Hirose N; Kawamura M; Arai Y
Atherosclerosis; 1999 Apr; 143(2):315-26. PubMed ID: 10217360
[TBL] [Abstract][Full Text] [Related]
2. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits.
de las Heras N; Aragoncillo P; Maeso R; Vazquez-Pérez S; Navarro-Cid J; DeGasparo M; Mann J; Ruilope LM; Cachofeiro V; Lahera V
Hypertension; 1999 Oct; 34(4 Pt 2):969-75. PubMed ID: 10523393
[TBL] [Abstract][Full Text] [Related]
3. Valsartan improves fibrinolytic balance in atherosclerotic rabbits.
Oubiña MP; de Las Heras N; Vázquez-Pérez S; Cediel E; Sanz-Rosa D; Ruilope LM; Cachofeiro V; Lahera V
J Hypertens; 2002 Feb; 20(2):303-10. PubMed ID: 11821716
[TBL] [Abstract][Full Text] [Related]
4. [The effect of captopril and valsartan on preventing the formation of atherosclerotic plaque].
Lu YS; Lei XY; DI J; Huang ST; Li JM
Zhonghua Nei Ke Za Zhi; 2005 Jun; 44(6):425-7. PubMed ID: 16008853
[TBL] [Abstract][Full Text] [Related]
5. Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors.
Chow L; De Gasparo M; Levens N
Eur J Pharmacol; 1995 Aug; 282(1-3):77-86. PubMed ID: 7498292
[TBL] [Abstract][Full Text] [Related]
6. Blockade of angiotensin converting enzyme but not of angiotensin AT1 receptors improves glucose tolerance.
Chow L; De Gasparo M; Levens N
Eur J Pharmacol; 1997 Jan; 319(1):77-83. PubMed ID: 9030901
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade.
Barker TA; Massett MP; Korshunov VA; Mohan AM; Kennedy AJ; Berk BC
Hypertension; 2006 Nov; 48(5):942-9. PubMed ID: 16982965
[TBL] [Abstract][Full Text] [Related]
8. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture.
Fennessy PA; Campbell JH; Campbell GR
Atherosclerosis; 1994 Mar; 106(1):29-41. PubMed ID: 8018105
[TBL] [Abstract][Full Text] [Related]
9. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
Stergiou GS; Skeva II; Baibas NM; Roussias LG; Kalkana CB; Achimastos AD; Mountokalakis TD
J Cardiovasc Pharmacol; 2000 Jun; 35(6):937-41. PubMed ID: 10836730
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
Yagi S; Morita T; Katayama S
Hypertens Res; 2004 Feb; 27(2):129-35. PubMed ID: 15005276
[TBL] [Abstract][Full Text] [Related]
11. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
12. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit.
Romero F; Rodríguez-Iturbe B; Pons H; Parra G; Quiroz Y; Rincón J; González L
Atherosclerosis; 2000 Sep; 152(1):127-33. PubMed ID: 10996347
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Zhu S; Liu Y; Wang L; Meng QH
Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
[TBL] [Abstract][Full Text] [Related]
15. Benazepril on tissue angiotensin-converting enzyme and cellular proliferation in restenosis after experimental angioplasty.
Li J; Wanchun C
J Cardiovasc Pharmacol; 1997 Dec; 30(6):790-7. PubMed ID: 9436819
[TBL] [Abstract][Full Text] [Related]
16. Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade.
Feng TC; Ying WY; Hua RJ; Ji YY; de Gasparo M
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):19-24. PubMed ID: 11881060
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive mechanism of action of the novel angiotensin converting enzyme inhibitor benazepril. Effect on isolated vascular preparations.
Kuroda K; Fukuda Y; Nakao K; Inukai T
Arzneimittelforschung; 1990 Sep; 40(9):968-73. PubMed ID: 2080946
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of perindopril, a novel angiotensin-converting enzyme inhibitor, on neointima formation after balloon injury in rats and cholesterol-fed rabbits.
Shibutani T; Kanda A; Ishigai Y; Mori T; Chiba K; Tanaka M; Tachizawa H
J Cardiovasc Pharmacol; 1994 Sep; 24(3):509-16. PubMed ID: 7799645
[TBL] [Abstract][Full Text] [Related]
19. An angiotensin converting enzyme inhibitor, perindopril, prevents progression of preformed atherosclerotic lesions in the cholesterol-fed rabbit.
Fennessy PA; Campbell JH; Campbell GR
Clin Sci (Lond); 1994 Dec; 87(6):685-91. PubMed ID: 7874860
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP.
Siragy HM; de Gasparo M; El-Kersh M; Carey RM
Hypertension; 2001 Aug; 38(2):183-6. PubMed ID: 11509473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
